Mouse model of in situ thromboembolic stroke and reperfusion

Stroke

Volumn 38, Issue 10, 2007, Pages 2771-2778

  Orset, Cyrille ^a   Macrez, Richard ^a   Young, Alan R ^a   Panthou, Didier ^b   Angles Cano, Eduardo ^a   Maubert, Eric ^a   Agin, Veronique ^a   Vivien, Denis ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b Laboratoire d'Anatomie Pathologique   (France)

Author keywords

Animal models; Embolic; Mouse; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; THROMBIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; STROKE; THROMBOEMBOLISM;

ANIMALS; CEREBRAL INFARCTION; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; INTRACRANIAL EMBOLISM; LASER-DOPPLER FLOWMETRY; MALE; MICE; MOTOR ACTIVITY; REPERFUSION; REPRODUCIBILITY OF RESULTS; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34848897581     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.487520     Document Type: Article

References (30)

1. Del Zoppo GJ. Investigational use of tPA in acute stroke. Ann Emerg Med. 1988;17:1196-1201.
2. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4:228-231.
3. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signalling. Nat Med. 2001;7:59-64.
4. Benchenane K, Berezowski V, Ali C, Fernandez-Monreal M, Lopez-Atalaya JP, Brillault J, Chuquet J, Nouvelo A, MacKenzie ET, Bu G, Cecchelli R, Touzani O, Vivien D. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related proteinmediated transcytosis. Circulation. 2005;111:2241-2249.
5. Benchenane K, Castel H, Boulouard M, Bluthe R, Fernandez-Monreal M, Roussel BD, Lopez-Atalaya JP, Butt-Gueulle S, Agin V, Maubert E, Dantzer R, Touzani O, Dauphin F, Vivien D, Ali C. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J Cell Sci. 2007;120:578-585.
6. Tamura A, Graham DI, McCulloch L, Teasdale GM. Focal cerebral ischemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1981;1:53-60.
7. Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN, Osterwalder T, Rülicke T, Sonderegger P. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci. 2001;18:443-457.
8. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
9. Welsh FA, Sakamoto T, McKee AE, Sims RE. Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse brain. J Neurochem. 1987;49:846- 851.
10. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study mice. Circulation. 1999;99:2440-2444.
11. Kudo M, Aoyama A, Ichimori S, Fukunaga N. An animal model of cerebral infarction. Homologous blood clot emboli in rats. Stroke. 1982;13:505-508.
12. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83-92.
13. Zhang ZG, Zhang L, Ding G, Jiang Q, Zhang RL, Zhang X, Gan WB, Chopp M. A model of mini-embolic stroke offers measurements of the neurovascular unit response in the living mouse. Stroke. 2005;36:2701-2704.
14. Atochin DN, Murciano JC, Gürsoy-Özdemir Y, Krasik T, Noda F, Ayata C, Dunn AK, Moskowitz MA, Huang PL, Muzykantov VR. Mouse model of microembolic stroke and reperfusion. Stroke. 2004;35:2177-2182.
15. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD. Induction of reproducible brain infarction by photochemicaly initiated thrombosis. Ann Neurol. 1985;17:497-504.
16. Nagai N, Zhao BQ, Suzuki Y, Ihara H, Urano T, Umemura K. Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice. J Cereb Blood Flow Metab. 2002;22:648-651.
17. Wang CX, Todd KG, Yang Y, Gordon T, Shuaib A. Patency of cerebral microvessels after focal embolic stroke in the rat. J Cereb Blood Flow Metab. 2001;21:413-421.
18. Niessen F, Hilger T, Hoehn M, Hossmann KA. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke. 2003;34:2019-2024.
19. Romanos E, Planas AM, Amaro S, Chamarro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab. 2007;27:14-20.
20. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx. 2005;2:396-409.
21. Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D, Yepes M. Tissue-type plasminogen activator-mediated shedding of astrocytic low density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood. 2007;109:3270-3278.
22. Tabrizi P, Wang L, Seeds N, McComb JG, Yamada S, Griffin JH, Carmeliet P, Weiss MH, Zlokovic BV. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model. Studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol. 1999;19:2801-2806.
23. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. 1995. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N Engl J Med. 333:1581-1587.
24. Liberator GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003;34:537-543.
25. Kilic E, Kilic Ü, Matter CM, Lüscher TF, Bassetti CL, Hermann DM. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversible by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke. 2005;36:332-336.
26. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus focal ischemia in spontaneously hypertensive rats. Stroke. 2002;33:2711-2717.
27. Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313-1317.
28. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence D. Tissue-type plasminogen activator induces opening of the blood- brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112:1533-1540.
29. Liot G, Benchenane K, Léveillé F, Lopez-Atalaya JP, Fernandez-Monreal M, Ruocco A, MacKenzie ET, Buisson A, Ali C, Vivien D. 2,7-bis-(4-amidinobenzylidene)-cycloheptan-1-one dihydrochloride, tPA Stop, prevent tPA-enhanced excitotoxicity both in vitro an in vivo. J Cereb Blood Flow Metab. 2004;24:1153-1159.
30. Lebeurrier N, Liot G, Lopez-Atalaya J-P, Orset C, Fernandez-Monreal M, Sonderegger P, Ali C, Vivien D. The brain-specific tissue type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol Cel Neurosci. 2005;30:552-558.